• CHM.AX is trading at A$0.05 (-5.45%) following recent company developments.
  • Chimeric Therapeutics announced on July 6, 2026, that an independent non-executive director retired from the board.
  • The company also initiated a strategic review on July 1, 2026, aimed at maximizing shareholder value, exploring options such as partnerships, licensing, and mergers.
  • Broader market sentiment was mixed on July 8, 2026, with the S&P 500 experiencing a slight decline (around 0.3-0.5%), while the Nasdaq Composite recorded a modest gain (around 0.1-0.2%).